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Abstract: Medical management of epilepsy seeks to eliminate or to reduce the frequency of seizures,
help patients maintain a normal lifestyle, and maintain psychosocial and occupational activities,
while avoiding the negative side effects of long-term treatment. Current FDA approved drugs have
been shown to have similar efficacy; however, they all share a commonality of having side effects
that have the potential to significantly reduce a patient’s quality of life. Cenobamate, a newly-FDA
approved drug used to treat partial-onset seizures in adult patients, has demonstrated promise in that
it works on two proposed mechanisms that are commonly associated with epilepsy. Cenobamate acts
as a positive allosteric modulator of the GABAA ion channels and is effective in reducing repetitive
neuronal firing by inhibition of voltage-gated sodium channels, although the complete mechanism
of action is currently unknown. The efficacy of Cenobamate with its low toxicity and adverse
drug reaction profile emphasizes the need to further evaluate antiepileptic therapies containing
sulfamoylphenyl and/or carbamate moieties in their chemical structure. Recent studies have found
more patients to be seizure free during the maintenance period when compared to placebo. The most
common side effects reported in with Cenobamate are somnolence, dizziness, headache, nausea,
and fatigue. There are currently ongoing phase III studies looking to further evaluate the long-term
benefits of Cenobamate and investigate adverse events.
Keywords: partial seizures; epilepsy; Cenobamate; antiepileptic drug; sulfamoylphenyl moieties;
XCOPRI; GABAA ion channels
1. Introduction
Seizure is often classified and further subclassified to describe paroxysmal events
of sudden onset neuronal firing resulting in a short period of altered neurologic func-
tion. There are many causes for seizures and seizure mimicking events such as syncope,
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migraine, stroke, and psychogenic nonepileptic seizures. After ruling out seizure mim-
ickers, the management of a new-onset, single seizure is driven by the determination of
the underlying cause. Seizures can result from an external cause (e.g., nonepileptic) or
an intrinsic dysfunction of the central nervous system. A baseline metabolic evaluation
should be done to evaluate the cause of a new seizure. This workup should start with an
evaluation of a patient’s complete metabolic panel and evaluation of medications that can
cause a disruption of metabolites causing a seizure or a medication that is known to have
seizures as a potential adverse reaction. An initial evaluation should also determine the
likelihood that a patient will have additional seizures, assist in the decision whether to
begin antiseizure drug therapy, and direct appropriate treatment to the underlying cause,
if identified. Once any treatable, systemic process is ruled out, as well as any treatable
underlying brain pathology, the identification of factors that increase the likelihood of
recurring seizures is often made. Then, a diagnosis of epilepsy may be considered.
Epilepsy is often diagnosed after an individual has two or more unprovoked seizures
greater than 24 h apart and can be explained as a disorder of an enduring predisposition
to generalized epileptic seizures [1]. In addition to this criteria, two other conditions that
are used clinically to diagnose epilepsy are a diagnosis of an epilepsy syndrome or one
unprovoked seizure and a probability of further seizures similar to the general recurrence
risk, at least 60%, after two unprovoked seizures, occurring over the next ten years [1].
The seizures occurring in epilepsy are often further classified into focal or generalized.
Generalized seizures refer to sudden onset neuronal firing affecting millions of neurons
in both hemispheres of the brain, typically with a loss of consciousness. A focal seizure is
defined by the sudden onset of neuronal firing with a very specific region of the brain that
may or may not result in the loss of consciousness. The degree of consciousness affected in a
focal seizure is often categorized as a focal seizure with awareness, impaired awareness, or
unknown awareness. Focal seizures can also be described as having a motor or nonmotor
component of the event. In a motor seizure, the predominating symptoms involve motor
activity, with sustained muscle tone, jerking, or atonic periods. Non-motor seizures are
often referred to as absence seizures due to the characteristic manifestation of staring into
space. Though generalized seizures are defined as having a loss of consciousness, they can
also be broken down into motor and nonmotor seizures.
While there has been a long-standing classification of epilepsies as focal or generalized,
two additional categories were added in 2017: generalized and focal epilepsy and unknown
if generalized or focal epilepsy [1]. These additions allow for the overlap that often occurs
between focal and generalized seizures, as many focal seizures (including awareness
and impaired awareness subtypes) may start focally but spread diffusely and become a
generalized seizure. The primary goal of this extensive classification system is to aid in
the research and development of antiepileptic treatments while maintaining a digestible
structure of the organization to epilepsy [2].
Treatment of epilepsy with antiseizure medication is frequently reserved for indi-
viduals who meet the criteria for a diagnosis of epilepsy, but in patients with a single
unprovoked seizure, it is difficult to assess the risk of recurrent seizures [2]. The initiation
of treatment is often subjected to a clinician’s judgment if the patient does not clearly meet
the criteria for a diagnosis of epilepsy [3]. Adults presenting with an unprovoked first
seizure and who immediately begin antiseizure medication reduces the risk of seizure
recurrence by approximately 35 percent over the next one to two years and almost half of
these patients on their first antiseizure drug trial will become seizure-free [2]. Finding an
antiseizure medication that successfully balances efficacy and adverse effects has proven to
be a difficult task. There are approximately thirty antiepileptic medications to choose from,
and no single medication has been proven to be marginally more effective with minimal
adverse reactions than other antiepileptic medications [2]. Current FDA approved drugs
have been shown to have similar efficacy, but they all also share a commonality of having
side effects that have the potential to significantly reduce a patient’s quality of life.
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2. Epidemiology of New-Onset Adult Epilepsy
Seizures affect eight to ten percent of the general population in a lifetime [4,5]. One
to two percent of emergency room visits are for seizures and of those seizures, 26% are
new-onset [6]. Almost half of new-onset seizures will present in adults over 65 years of
age [7,8]. There is a strong association between age and risk for developing epilepsy [9].
The incidence of new-onset epilepsy in adults over age 65, in various studies, is one to three
out of every 1000 people per year; this is two to six times higher than in the younger adult
populations [8–13]. Epilepsy prevalence is two to five percent in adults over age 65, which
is three to four times higher in younger adult populations [11,12]. Developing epilepsy
does not seem to differ greatly between genders. The incidence of adult, new-onset epilepsy
is slightly higher in females than in males [7,11].
A 2001 to 2005 study of US Medicare beneficiaries over age 65 demonstrated aver-
age annual incident rates were stratified by race. African Americans had the highest at
4.1 per 1000, then whites at 2.3 per 1000, and Asians and Native Americans were the lowest
at 1.6 and 1.1 per 1000, respectively [11]. A similar trend between races in younger and
older populations was shown in other studies, but the association between them remains
unexplained [12].
3. Pathophysiology of Epilepsy
Seizures are a hyperexcitable and hypersynchronous manifestation of a pathological
imbalance between excitatory and inhibitory factors (E/I imbalance) in neurotransmis-
sion [14]. Epilepsy is defined as recurrent, unprovoked seizures. Consideration of the
E/I imbalance can help guide an understanding of the pathophysiological mechanisms
of epilepsy. In adults, this balance is primarily struck between glutamate (an excitatory
neurotransmitter), GABA (an inhibitory neurotransmitter), and the extracellular potassium
concentration [14]. Phenobarbital and benzodiazapenes have historically been used to
prevent seizures or end an actively seizing patient’s seizure by working on the GABA
transmission mechanism [15]. Structural and physiologic abnormalities that alter the level
of these mediators influence the development of epileptic seizures. These abnormalities
can be genetic or acquired [16]. Mechanisms of these aberrancies can be attributable to an
array of neurovascular accidents such as traumatic, anoxic, inflammatory, genetic, or cryp-
togenic causes. Cryptogenic etiologies account for 25 to 50% of epilepsy cases [4,10,13,17].
Neurovascular etiologies of seizures account for approximately 50% of new-onset epilepsy
in adults over 65 [13]. These conditions create structural and functional changes that lead
to epilepsy.
Alterations in the E/I balance can occur at any level ranging from genetic muta-
tions to structural abnormalities in neuronal circuits. Genetic and structural pathologies
leading to epilepsy include abnormal ion channel function, abnormal neurotransmitter
transport proteins, abnormal neurotransmitter receptor function, and abnormal synaptic
connectivity [14,16]. Abnormal inward rectifying potassium channels, primarily within
astrocytes, lead to a high level of extracellular potassium after neuronal firing. Increases in
extracellular potassium result in neuronal hyperexcitability [14]. Glial cells have membrane
transporters responsible for removing extracellular glutamate to maintain healthy brain
function; dysfunction in these proteins can cause hyperexcitability resulting in epileptic
seizures [14].
Dysregulation of GABAergic transmission is theorized to play a role in epileptogene-
sis [14]. A well-known example of this is seen in Angelmann syndrome, where there are
documented abnormalities within GABA receptor subunits associated with epilepsy [16].
Inhibition of GABA transmission is associated with paroxysmal depolarization shift (PDS);
barbiturates and benzodiazapenes utilize this as their mechanism of action [15]. PDS is
characterized by abnormal fluctuations in neuronal membrane potential seen after an initial
depolarization by synaptic forces [14,18]. Two emerging ideas behind PDS are the “synap-
tic theory” and the “epileptic-neuron theory” [18]. The synaptic theory states excessive
stimulation of previously normal-functioning neurons via an aberrant recurrent synaptic
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feedback which causes abnormal depolarizations. The epileptic-neuron theory asserts that
the intrinsic neuronal properties of affected neurons alter conductance resulting in PDS [18].
The termination of a PDS is mediated by potassium and chloride conductance and GABA
receptors. Failure to terminate a PDS will result in a seizure [14]. Ultimately, seizures are
manifestations of a complex constellation of disturbances at multiple levels of cell structure
and function and of large neural network activity [14]
4. Risk Factors, Diagnosis, and Presentation of Epilepsy
Initial diagnostic evaluation for a first seizure should start with a complete history
and physical examination (H&P). The goal of the complete H&P is to characterize the
presentation of the seizure event, rule out other diagnoses, discern whether prior seizures
have occurred, and assess for underlying risk factors in the family history, past medical
history, and medications [19].
A history usually delineates between a focal and generalized seizure based on informa-
tion of preictal events, ictal behaviors, and postictal state. Asking directed questions about
circumstances just prior to a seizure can identify potential seizure precipitants or triggers
such as strong emotions, loud music, intense exercise, and flashing lights [20,21]. The
presentation of most seizures is abrupt onset, usually within seconds, and resolves within
a couple of minutes, for both generalized and focal seizures. Seizures that do not terminate
within a couple of minutes can indicate alternative conditions that are nonepileptic or a
potentially fatal outcome in an individual experiencing status epilepticus [19]. Alteration
of consciousness is associated with a generalized seizure; focal seizures can vary in their
disruption of consciousness. Patients with focal seizures without alteration in conscious-
ness can describe the seizure while some individuals experiencing a focal seizure may have
an impaired sense of consciousness and cannot recall the event. Focal seizures typically
present with localizing behaviors. For example, dysphasia insinuates the involvement of
the dominant hemisphere. The postictal period should last between 10 and 20 min and
gradually resolve. A prolonged postictal state could indicate residual seizure activity [19].
Physical examination is usually useful for identifying the causes of provoked seizures.
One of the most specific indicators of a seizure, more typically a tonic-clonic seizure, is
lateral tongue biting [22]. Risk factors for epilepsy include family history and previous
epileptic seizures. Past medical history can elucidate identifiable triggers, and events such
as trauma, specifically head trauma, may manifest as epilepsy later in life.
Laboratory studies include basic electrolytes, calcium, magnesium, glucose, complete
blood count, renal function, liver function, urinalysis, and toxicology screens to rule out
physiologic causes. Abnormal sodium is one of the more common electrolyte disturbances
observed to cause seizures and medications that can cause abnormal sodium leading to
seizures include all diueretics, selective serotonin reuptake inhibitors (SSRI), tramadol, and
serotonin and norepinephrine reuptake inhibitors (SNRI). An electroencephalograph (EEG)
is essential for the diagnostic evaluation of epileptic seizures [23,24]. EEG can help predict
recurrent seizures. An epileptiform abnormality and focal slowing of background rhythms
can be predictive; however, epileptiform discharges have a stronger predictive value [25].
The sensitivity and specificity of interictal epileptiform discharges, in adults, on EEG for
recurrent seizures is 17.3% and 94.7%, respectively [26]. In one study, this correlated with
a 77% and 47% post-test probability of seizure recurrence with and without noticeable
epileptiform discharges on EEG, respectively [25]. It has been supported that epileptiform
discharge present on EEG in the setting of a single unprovoked seizure is predictive of
recurrent seizure development [25]. Epilepsy is diagnosed after two unprovoked seizures
that are not attributable to reversible causes (electrolyte abnormalities, medication or
alcohol withdrawals) or traumatic brain injury that occur more than 24 h apart because the
risk of recurrence is over 60% [1].
5. Partial Onset Seizures in Adults
Pathophysiology, presentation, diagnosis, and risk factors.
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Partial seizures manifest as a result of pathogenic activation of a cortical area due to
pathological disinhibition. As aforementioned, a complex set of structural and functional
changes in neurons, glia, extracellular matrix, and neuro-glia vascular interface can occur
and be responsible for partial seizures [27,28]. Similar to epilepsy, these changes caused by
a primary insult (i.e., trauma, inflammation, anoxia, genetics, cerebrovascular accident) can
result in partial seizure years after the insult. As such, the risk factors for partial seizures
are similar to those for epilepsy.
These seizures usually present with neurological findings that can be localized in
the affected cortical region. Onset is usually rapid, associated with slowing background
activity on EEG, and the seizure only lasts a couple of minutes. They can present with or
without loss of consciousness and automatisms. Scalp EEG findings for partial seizures
are an initial slowing in background activity followed by a large, irregular amplitude
discharge, which transitions into rhythmic bursting followed by electrical depression [29].
Generalized seizures have large, irregular amplitude discharges from beginning to end of
the seizure [29]. Diagnosis is made clinically from history, physical, scalp EEG, and the rule
out of other possible diagnoses. The criteria for epilepsy diagnosis are aforementioned.
5.1. Pharmacologic Treatment
Medical management of epilepsy seeks to eliminate or reduce the frequency of seizures,
help patients maintain a normal lifestyle, and maintain psychosocial and occupational
activities while avoiding the negative side effects of long-term treatment [30]. The main
goal of antiepileptic drug (AED) therapy is to prevent seizures completely with limited
toxicity, adverse drug reaction, and consideration of comorbid conditions. In this pursuit,
AED therapy should be introduced early, especially for those patients who need to maintain
an active lifestyle, with careful consideration of the patient’s type of epilepsy, associated
neurological or medical issues, and comorbid conditions [30]. Treatment of new-onset
single seizure patients should be carefully considered, and initiation of treatment should
be weighed on the probability of recurrent seizures occurring and a diagnosis of epilepsy
being made [31].
Carbamazepine, phenytoin, and oxcarbazepine are the current, first-line treatment
options for partial seizures. Carbamazepine and phenytoin treat complex partial seizures in
adults, and oxcarbazepine can treat partial seizure, simple and complex, in adults [30]. Lev-
etiracetam and tiagabine are suitable for adjunctive treatment options. For every treatment
option, careful consideration should be given to side effects and the patient’s comorbidities.
5.2. Mechanical Treatment (Vagus Nerve Stimulation)
Vagal nerve stimulation (VNS) was introduced as an adjunctive therapy option in
those patients with medication-resistant epilepsy [32]. VNS is a surgical intervention to
place a neurocybernetic prosthetic implant that intermittently stimulates the left cervical
vagus nerve to suppress seizures [32]. VNS is a lower risk option compared to conventional
neurosurgical interventions that attempt to remove a seizure focus region [33]. VNS side
effects are coughing and hoarseness, which fluctuate with the level of stimulation provided
by the implant. VNS has been around since the 1980s and provides clinicians with a unique,
tested therapy that uses the natural peripheral and central connections of the vagus nerve
to control treatment-resistant seizures [32].
6. Cenobamate
6.1. Pharmacological Considerations
Cenobamate, sold under the brand name XCOPRI and also known as CNB, is a newly-
FDA approved drug used to treat partial-onset seizures in adult patients. It is distributed as
an oral tablet, and dosing starts at 12.5 mg daily. This drug has also been recently approved
by the European Commision (EC) and is sold in the European Union as Ontozry. It can be
titrated up but is not to exceed 400 mg once daily. Cenobamate acts as a positive allosteric
modulator of the GABAA ion channels and is effective in reducing repetitive neuronal firing
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by inhibition of voltage-gated sodium channels, but the complete mechanism of action is
currently unknown. In clinical trials, cenobamate was administered as adjunctive therapy
of 100 mg once daily [34]. Cenobamate increased phenytoin mean Cmax and area under the
curve (AUC) by 70% and 84%, respectively, and phenobarbital mean Cmax and AUC by 34%
and 37%, respectively [34]. Multiple doses of concomitant Cenobamate 200mg once daily
decreased carbamazepine mean Cmax and AUC, each by 23% [34]. No clinically significant
differences in the pharmacokinetics of the following drugs were seen with concomitant
cenobamate treatment: valproic acid, levetiracetam, or lacosamide [34]. The side effects
associated with cenobamate use were dose-dependent increases in somnolence, fatigue,
dizziness, gait disturbance, coordination disturbance, cognitive dysfunction, confusion,
and visual changes [34]. The serious adverse effects associated with cenobamate are drug
reaction with eosinophilia and systemic symptoms, QT shortening, suicidal behavior, and
suicidal ideation [34]. Initiation of CNB in patient’s taking multiple medication should be
carefully considered because some of the most commonly prescribed medications (SSRIs,
methadone, macrolides) can cause QT prolongation and arrhythmias can occur. Due to
these adverse effects, it is crucial to monitor other drugs or drug interactions that can
cause QT interval shortening and CNS depression, including alcohol. Cenobamate must
be renally dosed and is not recommended in those with end-stage renal disease [34].
Cenobamate should be used with caution in patients with mild to moderate hepatic
impairment and is not recommended in patients with severe hepatic impairment. More
research is necessary to further evaluate the use of cenobamate in individuals who are
pregnant or lactating and in the pediatric and geriatric populations [34].
6.2. Mechanism of Action
Cenobamate increases the inactivation of the fast and slow (transient) voltage-gated
sodium channels that facilitate the depolarization period of a neuronal action potential,
usually inactivated during repolarization. A percentage of these sodium channels remain
active during the downstroke of the action potential and are designated as persistent
sodium channels [35]. Cenobamate predominately exerts inhibitory effects on the persis-
tent sodium channels in the CA3 hippocampal neurons, an area with abundant axonal
networks, increasing its susceptibility to seizure potential [3]. Persistent sodium channels
have the ability to increase the number of recurrent action potentials in the neuron leading
to neuronal hyperexcitability [36]. The inhibition of both transient and persistent sodium
channels effectively diminishes both avenues of hyperexcitability in an epileptic hippocam-
pus by increasing the rate of entry into the inactivation phase and increasing the refractory
period of the action potential [37]. Cenobamate has a greater binding strength to the
inactivated state of the sodium channel, causing a more potentiated inactivation state [36].
Cenobamate has the ability to positively potentiate six out of the nineteen recognized
GABAA subunits in a concentration-dependent fashion to increase neuronal inhibition in
the overexcited pathways of the epileptic hippocampus [37]. Both tonic (outside of the
synapse) and phasic (synaptic) GABAA inhibitory neurons are positively potentiated by
cenobamate [38,39]. The GABAA subunits which cenobamate binds are distinct from the
subunits bound by benzodiazepines and non-benzodiazepines CNS depressants, such as
eszopiclone, as demonstrated by the inability of flumazenil to counteract the inhibitory ef-
fect of cenobamate [40]. The computation of inhibiting the persistent sodium channels and
enhancing GABAA receptor activity in CA3 hippocampal neurons has led to diminished
seizure effects [38,41].
6.3. Pharmacokinetics
The pharmacokinetic profile of cenobamate has been studied in general and special
populations. In one study, single (5 to 75 mg) and multiple (50 to 600 mg/day) oral
rising-dose of Cenobamate (capsule formation) in healthy individuals was found to have a
maximum plasma concentration between 0.8 and 4 h after oral administration [42]. The area
under the plasma concentration-time curve (AUC) after single-dose administration demon-
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strated that cenobamate increased more than in a dose-proportionate manner; however,
after multiple dosing from 50–500 mg/day, the AUC increased in a dose-proportionate
manner [42]. There are no significant repercussions in safety and tolerability from the
observed plasma accumulation in multiple dosing up to 500 mg/day [42]. For the single
dose, cenobamate shows a limited distribution in the body [42]. This is suggested by the
oral clearance and elimination rate constants staying analogous over the tested single-
dose range. Cenobamate has a half-life of 30 h for a 10 mg single dose, and 76 h for a
750 mg single dose [42]. For both doses, clearance increased in a dose-proportionate
manner, and steady-state was attained at approximately two weeks [42]. A second study
assessed the pharmacokinetic differences and dosing in renally impaired (RI), hepatic
impaired (HI), and elderly (>65 years) populations [37]. All subjects received a single
200 mg oral dose of cenobamate, and the results were compared to young (18–45 years)
and healthy adults [37]. The results demonstrated a 1.5-fold increase in AUC for mild to
moderate RI individuals, a 2-fold increase in AUC for mild to moderate HI individuals, and
no clinically significant findings were found between elderly and young individuals [37].
The differences in clearance for all three groups were insignificant [37]. Conclusively,
both doses of cenobamate generally have a mild side effect profile with the occasional
treatment-emergent adverse event, regardless of the AUC increasing non-proportionately
in the single-dose category [37]. Dosing adjustments need consideration for RI and HI
individuals, but not usually for the elderly [37,42].
7. Cenobamate Studies and Clinical Trials
7.1. Effects of Cenobamate on Voltage-Gated Sodium Channels in Rat Hippocampal CA3 Neurons
This project studied the mode of action of cenobamate in rat hippocampal CA3 pyra-
midal neurons. Using a whole-cell patch-clamp technique measuring membrane current,
the purpose of this study was to evaluate the effect cenobamate had on voltage-gated
sodium channels in the acutely isolated hippocampal CA3 neurons, sodium currents by
slow voltage-ramps, the voltage dependence of sodium channels, inactivation kinetics of
voltage-gated sodium channels, and the excitability of CA3 neurons. Cenobamate had
no effect on the time to peak or the weighted decay time constant of transient time to
peak. Concerning the effect of cenobamate on voltage dependence when conductance at
each voltage was normalized to the maximal conductance, cenobamate concentrations at
≤100 µM did not change the half-maximal voltage for activation (−38.2 ± 4.1 mV and
−37.9 ± 4.3 mV in the absence and presence of cenobamate, 0.3 ± 0.2 mV shift, n = 8,
p = 0.41). The midpoint voltage was shifted for inactivation (V50,inact) toward a hyperpolar-
izing range in a concentration-dependent manner; 100 µM cenobamate shifted the V50,inact
from −59.1 ± 3.1 to −65.0 ± 2.6 mV (−5.9 ± 2.6 mV shift, n = 8, p < 0.01). Concerning
the excitability of CA3 neurons, cenobamate reduced neuronal excitability by inhibiting
the non-inactivating persistent component of the current of sodium but had no effect on
voltage-gated calcium and potassium channels or excitatory receptors [38].
7.2. Effects of Cenobamate on GABA-A Receptor Modulation
A 2019 study analyzed the effect of cenobamate on GABAA receptors and GABA-
mediated currents using radioligand binding assays to investigate the binding of the
cenobamate on the GABAA receptors sites in rat hippocampal CA3 neurons, dentate gyrus,
and mouse and rat CA1 hippocampal neurons. The experiment used whole-cell patch-
clamp assays to gather electrophysical recordings. Relative activity of GABAA receptors
was analyzed on six human GABAA ion channel subtypes expressed in heterologous cells.
Cenobamate did not significantly displace the binding of GABA, muscimol, flunitrazepam,
or flumazenil to GABAA receptors. Cenobamate did significantly displace the binding
of TBPS radioligand to GABA-gated Cl- channel. Cenobamate in the rat hippocampal
neurons significantly increased the GABA-induced current in a concentration-dependent
manner. The drug’s potentiation of GABA-induced currents was not affected by flumazenil.
In mouse CA1 neurons, cenobamate significantly delayed the decay of evoked inhibitory
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postsynaptic currents without affecting the peak amplitude. Most prominently in rat
CA1 neurons, cenobamate enhanced tonic GABAA currents in a concentration-dependent
manner. This effect was also seen to a lesser degree in the rat dentate gyrus [41].
7.3. Suppression of the Photoparoxysmal Response in Photosensitive Epilepsy with Cenobamate
One single-blind study evaluated the efficacy of cenobamate by assessing its effect on
photoparoxysmal-EEG responses to intermittent photic stimulation (IPS) in adults with
photosensitive epilepsy [43]. The participants underwent photic stimulation intermittently
under three different eye conditions: eye closure, eyes closed, and eyes opened. This
stimulation was done after they were either given a placebo or a dose of cenobamate.
Cenobamate was dosed at 100 mg, 250 mg, or 400 mg, with data recorded from a total of
six patients. Levels of epileptic activity suppression on EEG were seen in a dose-dependent
fashion. Starting with the 100-mg dose level, cenobamate produced partial suppression of
IPS sensitivity in 33% of patients under eyes-closed condition. Complete suppression of
IPS sensitivity in 25% of patients and partial suppression of IPS sensitivity in 100% when
given the 250 mg dose. The 400-mg dose produced complete suppression of IPS sensitivity
in 25% of patients, and partial suppression in 50% patients in at least one eye condition [43].
There were no deaths seen in the study, and no treatment-emergent adverse events leading
to discontinuation. Adverse effects reported include orthostatic hypotension with syncope
in one patient, postural dizziness, and somnolence in three patients. Adverse effects were
independent of increased dose levels.
7.4. Randomized Phase 2 Study of Adjunctive Cenobamate in Patients with Uncontrolled
Focal Seizures
A randomized phase 2 study in 2020 evaluated the efficacy and safety of using
200 mg/d of cenobamate as adjunctive therapy in patients with uncontrolled focal seizures.
The course of the study was 12 weeks, which included a 6-week titration phase and a
6-week maintenance phase. Participants were randomized, and the study was designed as
double-blind with placebo control. Patients received a 50 mg dose of either cenobamate
or placebo once a day. The dose was up titrated by 50 mg per day every two weeks until
a target dose of 200 mg was met to start the maintenance phase. Percent change from
baseline in focal seizure frequency per 28 days was used as a measurement of the primary
efficacy outcome [44]. A total of 201 out of an initial 222 patients completed the study and
were included in the intent to treat population. A significant median percent reduction was
seen in seizure frequency when comparing the cenobamate-treated and placebo-treated
patients. The median focal seizure frequency per 28 days during double-blind treatment
decreased from 7.5 at baseline to 3.8 for the cenobamate group and from 5.5 at baseline
to 5.0 for the placebo group. This translates to a median percent reduction in seizure
frequency per 28 days of 55.6% and 21.5% for cenobamate-treated patients and placebo-
treated patients, respectively (p < 0.0001) [44]. Adverse events observed in the treatment
group throughout this 12-week study include somnolence dizziness, headache, nausea,
and fatigue. Somnolence and dizziness were the most frequently reported, both at 22.1%.
Urinary tract infections occurred in 8% of the cenobamate treated patients compared to
1.8% of placebo patients, and nasopharyngitis occurred in 6.2% of cenobamate-treated
patients compared to 0.9% of placebo patients. Ultimately, cenobamate appeared to cause
fairly mild or moderate treatment-emergent adverse events (TEAEs) when compared to the
placebo. This is demonstrated through findings showing that TEAEs that occurred in >5%
of cenobamate-treated patients with a ≥5% difference over the placebo group included
somnolence (22.1% vs. 10.1%), dizziness (20.4% vs. 13.8%), balance disorder (7.1% vs.
0.9%), and nystagmus (9.7% vs. 0%) [44].
7.5. Safety and Efficacy of Adjunctive Cenobamate
In addition to the study above, another 2020 study evaluated the efficacy and safety
of adjunctive cenobamate in patients with focal seizures. Similarly, the study design was
double-blinded, random, and placebo-controlled. A 12-week period divided into a 6-week
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titration and 6-week maintenance phase was also used. However, in this clinical trial, the
groups were assigned dosages 100 mg, 200 mg, 400 mg, or placebo. Efficacy outcomes
were assessed by the percent change in 28-day focal seizure frequency and then analyzed
with a hierarchal step-down procedure that compared the 400 mg, 200 mg, and 100 mg
individually to the placebo [45]. Percent change did not appear to differ significantly
between the 200 mg and 400 mg groups, though it did differ from the 100 mg group.
This is reflected in the finding that the percentage changes in seizure frequency were
−24.0% for the placebo group compared to −35.5% (−62.5 to −15.0%; p = 0.0071) for the
100 mg dose group, −55.0% (−73.0 to −23.0%; p < 0.0001) for the 200 mg dose group,
and −55.0% (−85.0 to −28.0%; p < 0.0001) for the 400 mg dose group [45]. Vossler et al.,
in doing a commentary on this trial, found that the median modal dose reported in the
400 mg group should have actually been 300 mg as opposed to 400 mg. This is attributed
to the fact that an antiseizure medication possesses a longer half-life therefore a longer
titration period is preferable. On taking this into account, Vossler et al. looked at the
results of only the modified, intent to treat treatment phase maintenance phase cohorts and
adjusted the dose-response median percent seizure reductions. The outcome of this was
reductions in median percent seizures to 25%, 40%, 56%, and 65% for the placebo and CNB
100, 200, and 400 mg cohorts, respectively. The 65% reduction at the maximum dose is
greater than that seen in any of the pivotal studies on all the second- and third-generation
antiseizure medications [46]. This data is based on an analysis that was reported by
Chen et al. in 2018 on the seizure-free rate of first, second, and third-generation antiseizure
medications. The adverse events seen in this trial were similar to those seen in others,
with TEAEs appearing as relatively mild or moderate (somnolence, dizziness, fatigue, etc.).
This is seen in the occurrence of 68% in the placebo group, 55% in the 100 mg group, 66%
in the 300 mg group, and 82% in the 400 mg group. Serious events (ataxia, nystagmus,
vertigo, etc.) appeared as less of a correlation with dose relation and were seen in 6%
of the placebo group, 9% of the 100 mg group, 4% of the 200 mg, and 7% of the 400 mg
group [46]. Of note, three severe hypersensitivity reactions occurred during this study.
There was one reported case of DRESS in a patient who was assigned the 200 mg/day
dose of cenobamate; it is hypothesized that this may be linked to a faster titration protocol
than was originally performed [45]. A phase III trial is currently active (ClinicalTrials.gov
identifier: NCT02535091) exploring the adverse events, such as DRESS, with the intention
of exploring titration relationships. A currently recommended dosing titration schedule is
being used, and so far, no cases of DRESS have been reported [35].
7.6. Cenobamate: A New Adjunctive
Until this point, the efficacy and safety of the clinical studies discussed were focused
on the short-term outcomes. The clinical study discussed in the previous paragraph showed
enough positive outlook in the short-term phase to allow for an open-label extension. This
allowed for the evaluation of long-term efficacy and safety of cenobamate. In this phase,
long term efficacy outcomes were reported as the change in seizure frequency per month,
and safety outcomes were reported as adverse events. The target dose of cenobamate was
300 mg/day, with 400 mg set as the maximal limitation. A total of 355 patients from the
double-blind study entered the open-label extension. Of these patients, 35.3% discontinued
therapy, 15.5% due to lack of efficacy, and 6.8% due to adverse events [47]. Though TEAEs
only led to discontinuation in 6.8% of patients, 87.6% of patients experienced some form of
TEAE. Serious adverse events were defined as seizures and vertigo; these events were seen
in 18.3% of patients. The more common TEAEs occurring in greater than 10% of patients
were dizziness, somnolence, headache, diplopia, fatigue, and gait disturbance [47]. In the
patients who did not discontinue medication, a median reduction of seizure frequency was
reported as 76% at 25–30 months, with 20.2% of patients being completely seizure-free at
25–30 months [47]. There are two phase-3 clinical trials that are still active and exploring
long-term efficacy and safety, as well as pharmacokinetic measurements. The first of
these was discussed previously in relation to DRESS and is estimated to be completed
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in December 2020; the other study is estimated to be completed in November 2023 [35].
Table 1 is a summary of the studies discussed in this section.
Table 1. Summary of Studies.
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8. Conclusions
Cenobamate inhibits persistent sodium channels and induces GABAA inhibitory
currents to control epileptic seizures. The pharmacokinetic profile demonstrates a dose
dependent plasma concentration for the multiple dosing category and more than a dose
dependent plasma concentration for the single dosing category. Furthermore, a long half-
life with limited distribution was observed and dose adjustments are only required for
hepatic and renally impaired individuals.
Cenobamate shows promise in that it works on two neuronal ion channels that are
commonly associated with epilepsy. Furthermore, it has also proven to be efficacious as
an adjunctive therapy in a wide range of epileptic syndromes in either decreasing the
seizure frequency or completely suppressing all seizures. In addition to this, the reported
adverse effects have appeared to be relatively mild, with the most severe being one reported
case of DRESS. This has continued to hold true in terms of long-term outcomes as well.
Cenobamate is a relatively new drug that shows potential and merit in the continuing
research for an antiepileptic drug that demonstrates superiority and clinical significance.
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